Trial · NCT03067441
Outcomes17
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Up to Week 82 | Safety Population: all enrolled participants who received at least 1 dose of bempedoic acid in the OLE Study | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percent Change From Parent Study Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 52 and 78 | Baseline; Week 52 and Week 78 | Safety Population. Only participants with available data were analyzed. | percent change | MEAN |
| SECONDARY | Mean Change From Parent Study Baseline in LDL-C at Weeks 52 and 78 | Baseline; Week 52 and Week 78 | Safety Population. Only participants with available data were analyzed. | milligrams per deciliter (mg/dL) | MEAN |
| SECONDARY | Percent Change From Parent Study Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 52 and 78 | Baseline; Week 52 and Week 72 | Safety Population. Only participants with available data were analyzed. | percent change | MEAN |
| SECONDARY | Percent Change From Parent Study Baseline in Total Cholesterol at Weeks 52 and 78 | Baseline; Week 52 and Week 78 | Safety Population. Only participants with available data were analyzed. | percent change | MEAN |
| SECONDARY | Percent Change From Parent Study Baseline in Apolipoprotein B (ApoB) at Weeks 52 and 78 | Baseline; Week 52 and Week 78 | Safety Population. Only participants with available data were analyzed. | percent change | MEAN |
| SECONDARY | Percent Change From Parent Study Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) at Weeks 52 and 78 | Baseline; Week 52 and Week 78 | Safety Population. Only participants with available data were analyzed. | percent change | MEDIAN |
| SECONDARY | Percent Change From Parent Study Baseline in Triglycerides at Weeks 52 and 78 | Baseline; Week 52 and Week 78 | Safety Population. Only participants with available data were analyzed. | percent change | MEDIAN |
| SECONDARY | Percent Change From Parent Study Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Weeks 52 and 78 | Baseline; Week 52 and Week 78 | Safety Population. Only participants with available data were analyzed. | percent change | MEAN |
| SECONDARY | Percent Change From Open-Label Extension (OLE) Study Baseline in LDL-C at Weeks 52 and 78 | Baseline; Week 52 and Week 78 | Safety Population. Only participants with available data were analyzed. | percent change | MEAN |
| SECONDARY | Mean Change From OLE Baseline in LDL-C at Weeks 52 and 78 | Baseline; Week 52 and Week 72 | Safety Population. Only participants with available data were analyzed. | mg/dL | MEAN |
| SECONDARY | Percent Change From OLE Baseline in Non-HDL-C at Weeks 52 and 78 | Baseline; Week 52 and Week 78 | Safety Population. Only participants with available data were analyzed. | percent change | MEAN |
| SECONDARY | Percent Change From OLE Baseline in Total Cholesterol at Weeks 52 and 78 | Baseline; Week 52 and Week 78 | Safety Population. Only participants with available data were analyzed. | percent change | MEAN |
| SECONDARY | Percent Change From OLE Baseline ApoB at Weeks 52 and 78 | Baseline; Week 52 and Week 78 | Safety Population. Only participants with available data were analyzed. | percent change | MEAN |
| SECONDARY | Percent Change From OLE Baseline in Hs-CRP at Weeks 52 and 78 | Baseline; Week 52 and Week 78 | Safety Population. Only participants with available data were analyzed. | percent change | MEDIAN |
| SECONDARY | Percent Change From OLE Baseline in Triglycerides at Weeks 52 and 78 | Baseline; Week 52 and Week 78 | Safety Population. Only participants with available data were analyzed. | percent change | MEDIAN |
| SECONDARY | Percent Change From OLE Baseline in HDL-C at Weeks 52 and 78 | Baseline; Week 52 and Week 78 | Safety Population. Only participants with available data were analyzed. | percent change | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03067441/outcomes